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Abstract
Objectives: The purpose of this study was to determine the relationship between carbohydrate antigen
(CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with
neoadjuvant therapy (NT).
Methods: This study included all patients with borderline resectable pancreatic cancer, a serum CA 19-9
level of40 U/ml and bilirubin of2 mg/dl, in whom NT was initiated at one institution between 2001 and
2010. The study evaluated the associations between pre- and post-NT CA 19-9, resection and overall
survival.
Results: Among 141 eligible patients, CA 19-9 declined during NT in 116. Following NT, 84 of 141 (60%)
patients underwent resection. For post-NT resection, the positive predictive value of a decline and the
negative predictive value of an increase in CA 19-9 were 70% and 88%, respectively. The normalization
of CA 19-9 (post-NT <40 U/ml) was associated with longer median overall survival among both non-
resected (15 months versus 11 months; P = 0.022) and resected (38 months versus 26 months; P = 0.020)
patients. Factors independently associated with shorter overall survival were no resection [hazard ratio
(HR) 3.86, P < 0.001] and failure to normalize CA 19-9 (HR 2.13, P = 0.001).
Conclusions: The serum CA 19-9 level represents a dynamic preoperative marker of tumour biology and
response to NT, and provides prognostic information in both non-resected and resected patients with
borderline resectable pancreatic cancer.
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Introduction
Serum carbohydrate antigen (CA) 19-9 is the most common
tumour marker used in the clinical management of patients with
pancreatic ductal adenocarcinoma (PDAC).1–5 Among patients
with radiographically resectable PDAC, CA 19-9 has been used as
an indicator of clinically occult metastatic disease,5 as a criterion
for the use of diagnostic laparoscopy prior to surgery,3,4 as a prog-
nostic marker following resection with or without adjuvant
therapy6,7 and as a director of therapy following postoperative
recurrence.8 Among patients with unresectable, locally advanced
or metastatic disease, CA 19-9 has been used as a prognostic
marker for survival, as well as an indicator of response to palliative
therapies.1,7,9
Borderline resectable PDAC, irrespective of the radiographic
criteria used to define it, represents a challenging subset of cancer
manifestations with local tumour anatomy that lies between the
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clearly resectable and unresectable.10–12 Because patients with bor-
derline resectable cancers are at high risk for margin-positive
resection and early disease progression following surgery, patients
with this stage of disease are routinely administered neoadjuvant
therapy (NT) prior to planned resection.10,12–15 The goals of this
treatment strategy include the achievement of local control of the
primary tumour, sterilization of lymphadenopathy and surgical
margins, early treatment of presumed micro-metastatic disease,
and the evaluation of tumour biology prior to a potentially
morbid abdominal operation.12,14
Although there is consensus that the use of chemotherapy
and/or chemoradiation prior to surgical resection is rational in
patients with borderline resectable PDAC, few data exist to guide
the details of such management.10,14 The relative importance of
chemotherapy and chemoradiation, the ideal sequence and dura-
tion of their administration, and the precise cytotoxic agents to be
used in the individual patient are all unclear. In this regard, one of
the primary obstacles to the assessment and optimization of mul-
timodal treatment strategies is the absence of a well-defined clini-
cal indicator of response to preoperative therapy. An inexpensive,
reproducible and easily measured response metric would be clini-
cally useful to evaluate the efficacy of different preoperative regi-
mens, to determine the optimal duration of each component
of multimodal therapy and to estimate prognosis following
treatment.
The current authors previously demonstrated that the response
of PDAC to NT can be estimated by histopathologic examination
of the resected primary tumour. Fibrosis and a marked reduction
in the residual viable cancer cells following the administration of
NT were associated with a favourable prognosis and may reflect
clinically significant cytotoxic activity.16 However, because a his-
tologic evaluation of tumour response requires an examination of
tumour cells and tissue architecture, this dynamic measure of
tumour response is unavailable in the preoperative setting. Fur-
thermore, although the change in tumour size as determined
radiographically and as classified using RECIST (response evalu-
ation criteria in solid tumours) parameters can be used to estimate
response to therapy in patients with many types of cancer, the
current authors have previously demonstrated that radiographic
‘response’ is rare among patients with borderline resectable PDAC
treated with NT and, further, when observed, it is not associated
with a favourable outcome among patients who undergo subse-
quent resection.17
Using data from two clinical trials of neoadjuvant chemoradia-
tion, the current authors previously demonstrated that serum CA
19-9 levels can provide some clinically relevant prognostic infor-
mation in patients with potentially resectable PDAC treated with
NT.2,18–20 On this basis, the present study was conducted to verify
the hypothesis that a change in CA 19-9 during NT can be used as
a surrogate marker of tumour biology and response to therapy in
patients with borderline resectable PDAC. The first objective of
this analysis was to evaluate the change in serum CA 19-9 from
baseline following NT in patients treated for borderline resectable
PDAC. The primary aim was to evaluate the association between
CA 19-9 levels and survival in this important group of patients.
Materials and methods
Patient selection and definitions
This study was approved by the institutional review board of the
University of Texas MD Anderson Cancer Center (MDACC). The
institution’s prospectively maintained pancreatic translational
database21 was queried for all patients with PDAC who were
treated with neoadjuvant chemotherapy and/or chemoradiation
and subsequently underwent restaging and consideration for
surgery during the period 2001–2010. Strict anatomic staging cri-
teria were assessed by multi-detector, contrast-enhanced com-
puted tomography (CT).12,17 Included in this study were all
patients who presented with primary tumour anatomy that met
either MDACC criteria11,12 or those of the Americas Hepato-
Pancreato-Biliary Association (AHPBA), the Society of Surgical
Oncology (SSO) and the Society for Surgery of the Alimentary
Tract (SSAT)10 for borderline resectable PDAC (Table 1), in whom
serum CA 19-9 was assayed both prior and subsequent to the
delivery of NT, and in whom an abnormal CA 19-9 level (defined
as 40 U/ml) prior to treatment was established. Patients with
baseline CA 19-9 levels obtained in association with a total
bilirubin level of >2 mg/dl were excluded as biliary obstruction
can lead to an artificial increase in serum CA 19-9 (Fig. 1).22
Neoadjuvant therapy and treatment schema
The current authors routinely treated patients with potentially or
borderline resectable PDAC with chemoradiation prior to surgical
resection. Systemic chemotherapy was delivered selectively prior
to chemoradiation, most commonly to patients meeting MDACC
anatomic or clinical criteria for borderline resectable dis-
ease.11,12,18,20 Biliary decompression was generally accomplished
with a metal endobiliary stent prior to the initiation of therapy.
The patients reported in this study received chemoradiation
based on gemcitabine or 5-fluorouracil with or without induction
gemcitabine-based systemic chemotherapy in the neoadjuvant
setting.19,20,23 Prior to (‘pre-NT’) and following (‘post-NT’) the
administration of NT, patients underwent a comprehensive
staging evaluation that routinely included a measurement of
serum CA 19-9. Serum samples acquired prior to 6 October 2004
were assayed for CA 19-9 by Quest Diagnostics, Inc. (Madison, NJ,
USA). Subsequent samples were assayed using a similar method at
MDACC.
Criteria for surgical resection following completion of NT
included: (i) a performance status sufficient for major abdominal
surgery; (ii) the adequate optimizing of comorbidities, and (iii) no
radiographic or intraoperative detection of tumour progression.18
Serum CA 19-9 was not used as a primary criterion for surgery.
Follow-up
Following resection, patients were evaluated in an intensive sur-
veillance programme every 3–4 months, with an institutional bias
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toward aggressive treatment of recurrence.24,25 Patients who did
not undergo resection following the receipt of NT generally
received palliative gemcitabine-based chemotherapy during this
period.
Statistical analyses
Chi-squared and Fisher’s exact tests were used to compare non-
parametric categorical variables. The Mann–Whitney U-test was
used to compare non-parametric continuous variables. A receiver
operating characteristic (ROC) curve was constructed to evaluate
the relationship between CA 19-9 level and the prediction of
resection versus no resection after NT. The area under the curve
(AUC) was calculated for pre-NT CA 19-9 and for post-NT CA
19-9 to compare the relative value of each test. Optimal cut-off
values were determined graphically to maximize sensitivity and
specificity simultaneously. Overall survival (OS) was defined as
the interval between tissue diagnosis and death or last follow-up.
Durations of OS associated with various CA 19-9 cut-off values
were estimated using the Kaplan–Meier method and compared
using the log-rank test. Clinically significant univariate factors
were included in multivariate Cox regression models, as were
statistically significant (P < 0.05) univariate factors associated
with OS to determine independent associations with OS. Statisti-
cal analyses were performed using spss Statistics Version 19 (IBM
Corp., Armonk, NY, USA). All tests were two-sided; differences of
statistical significance were indicated by a P-value of <0.05.
Results
Patients and treatment outcomes
During the study period, 210 patients presented with a primary
tumour that met MDACC or AHPBA/SSO/SSAT anatomic crite-
ria for borderline resectable PDAC and with serum CA 19-9 levels
measured both before and after the delivery of NT. Of these, 40
patients were excluded because their pre-NT CA 19-9 levels were
associated with jaundice. An additional 29 of the remaining 170
(17%) patients had normal or undetectable (n = 6) pre-NT CA
19-9 levels and were excluded.
Of the remaining 141 patients evaluated in this study, 84 (60%)
underwent pancreatectomy after NT. The demographics and base-
line clinical profiles of resected and non-resected patients were
similar (Table 2). Median follow-up in resected and non-resected
patients was 24.2 months (range: 5–113 months) and 12.0 months
(range: 3–77 months), respectively. The median durations of OS
in all patients, resected patients and non-resected patients were
19.1 months [95% confidence interval (CI) 13.9–24.3 months],
Table 1 Classifications of localized pancreatic adenocarcinoma as defined by the Americas Hepato-Pancreato-Biliary Association (AHPBA),
the Society of Surgical Oncology (SSO) and the Society for Surgery of the Alimentary Tract (SSAT), and MD Anderson Cancer Center.
Adapted from Katz et al. (2012)17
AHPBA/SSO/SSAT10 MD Anderson Cancer Center11,12
Potentially
resectable
Borderline
resectable
Locally advanced Potentially
resectable
Borderline
resectable
Locally
advanced
SMV/PV No abutmenta or
encasementb
Abutment, encasement
or occlusion
Not reconstructible Abutment or encasement
without occlusion
Short segment
occlusion
Not reconstructible
SMA No abutment or
encasement
Abutment Encasement No abutment or
encasement
Abutment Encasement
CHA No abutment or
encasement
Abutment or
short segment
encasement
Long segment
encasement
No abutment or
encasement
Abutment or
short segment
encasement
Long segment
encasement
CT No abutment or
encasement
No abutment or
encasement
Abutment No abutment or
encasement
Abutment Encasement
a180 degrees of vessel circumference.
b>180 degrees of vessel circumference.
SMV, superior mesenteric vein; PV, portal vein; SMA, superior mesenteric artery; CHA, common hepatic artery; CT, coeliac trunk.
40 patients with total
bilirubin of > 2.0 mg/dl
210 patients with borderline
resectable pancreatic cancer
170 patients 
141 patients 
6 patients with CA 19-9 of < 1 U/ml
23 patients with CA 19-9 of < 40 U/ml
CA 19-9 CA 19-9 =
116 patients 25 patients 
Figure 1 Flow diagram of patients selected for this study. CA 19-9,
carbohydrate antigen 19-9 (serum)
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30.9 months (95% CI 26.8–35.0 months) and 12.0 months (95%
CI 9.3–14.7 months), respectively (P < 0.001). Detection of metas-
tases at restaging or at surgery was the most common reason
for failure to undergo pancreatectomy following NT (37 of 57
patients, 65%) (Table 2).
Serum CA 19-9 before and after NT
The median CA 19-9 level in non-resected patients was higher
than that in resected patients both prior to (368 U/ml versus
211 U/ml; P = 0.020) and following (222 U/ml versus 49 U/ml;
P < 0.001) the administration of NT (Table 2). Serum CA 19-9 in
116 of 141 (82%) patients declined over the course of NT by a
median of 72% (range: 0.3–99%) and normalized in 47 (33%)
patients. Serum CA 19-9 in 25 (18%) patients increased by a
median of 109% (range: 0–564%) or did not change (n = 1)
(Fig. 2).
Table 2 Clinicopathologic profile of patients with borderline resectable pancreatic adenocarcinoma, non-resected and resected after
neoadjuvant therapy (NT)
Clinical characteristic All patients Patients not resected after NT Patients resected after NT P-value
Patients, n 141 57 84
Baseline data (pre-NT)
Age, years, median (range) 63 (34–81) 66 (38–81) 63 (35–79) 0.244
Sex, female, n (%) 74 (52.5%) 25 (43.9%) 49 (58.3%) 0.091
Race, White, n (%) 115 (81.6%) 48 (84.2%) 67 (79.8%) 0.611
Head/uncinate (versus body/tail), n (%) 126 (89.4%) 52 (91.2%) 74 (88.1%) 0.554
CA 19-9, U/ml, median (range) 274 (42–8662) 368 (46–5687) 211 (42–8662) 0.020
CA 19-9 < 100, n (%) 34 (24.1%) 11 (19.3%) 23 (27.4%) 0.271
CA 19-9 < 200, n (%) 61 (43.3%) 21 (36.8%) 40 (47.6%) 0.205
CA 19-9 < 1000, n (%) 113 (80.1%) 36 (63.2%) 77 (91.7%) <0.001
Post-NT serum CA 19-9 data
CA 19-9, median (range) 73 (1–17171) 222 (9–17171) 49 (1–2908) <0.001
CA 19-9 decrease (any %), n (%) 116 (82.3%) 35 (61.4%) 81 (96.4%) <0.001
CA 19-9 of <40 U/ml (normalized), n (%) 47 (33.3%) 12 (21.1%) 35 (41.7%) 0.011
CA 19-9 of <100 U/ml, n (%) 81 (57.4%) 17 (29.8%) 64 (76.2%) <0.001
CA 19-9 of <200 U/ml, n (%) 101 (71.6%) 27 (47.4%) 74 (88.1%) <0.001
CA 19-9 of <1000 U/ml, n (%) 125 (88.7%) 42 (73.7%) 83 (98.8%) <0.001
Reason for non-resection, n (%)
Metastases 37 (64.9%)
Local anatomy 13 (22.8%)
Performance status 12 (12.3%)
Postoperative characteristics, n (%)
Tumour size >2 cm 40 (47.6%)
Lymph node negative 43 (51.2%)
Lymph node ratio of <0.1 66 (78.6%)
Lymph node ratio of <0.15 74 (88.1%)
Margin negative 77 (91.7%)
Complete pathologic response 9 (10.7%)
CA 19-9, carbohydrate antigen 19-9 (serum).
Figure 2 Pattern of carbohydrate antigen (CA) 19-9 change after
neoadjuvant therapy showing that 82% of patients experienced a
decrease in CA 19-9
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Association between CA 19-9 change and
resection status
The post-NT CA 19-9 level was more informative as a predictor of
failure to undergo pancreatectomy than the pre-NT level based on
ROC analysis (Fig. 3). For predicting resection after NT, the AUCs
for pre-NT and post-NT CA 19-9 levels were 0.62 (95% CI 0.52–
0.71; P < 0.020) and 0.78 (95% CI 0.70–0.86; P < 0.001) with
optimum cut-off values of 989 U/ml (pre-NT) and 106 U/ml
(post-NT), respectively.
In all, 81 of 116 patients in whom CA 19-9 decreased during NT
underwent resection [positive predictive value (PPV): 70%] and
22 of 25 patients in whom CA 19-9 increased did not undergo
resection [negative predictive value (NPV): 88%].
Change in CA 19-9 as a prognostic marker of OS
At post-NT CA 19-9 cut-offs of 1000 U/ml, 200 U/ml and 100 U/
ml, low CA 19-9 was associated with a longer median OS in
non-resected but not in resected patients (Table 3). Normalization
of CA 19-9 was associated with a longer median OS among both
resected [37.9 months (95% CI 30.5–45.3) versus 26.0 months
(95% CI 19.6–32.4); P < 0.020] and non-resected patients [15.0
months (95% CI 7.6–22.4) versus 11.0 months (95% 9.4–12.6);
P = 0.022] (Fig. 4).
Multivariate survival model
For all patients, only resection and CA 19-9 normalization were
significant covariates associated with OS. By multivariate analysis,
both resection [hazard ratio (HR) 3.86, 95% CI 2.58–5.81; P <
0.001] and normalization of CA 19-9 (HR 2.13, 95% CI 1.37–3.22;
P = 0.001) were independent factors associated with prolonged
OS. Among resected patients, after adjusting for clinically relevant
covariates (tumour size, margin status, lymph node status or
ratio) which were entered into the multivariate analysis, only nor-
malization of CA 19-9 remained independently associated with
OS (HR 1.92, 95% CI 1.08–3.42; P = 0.027).
Discussion
The purpose of this study was to characterize the relationships
between pre- and post-treatment serum CA 19-9 levels, and onco-
logic outcome following multimodal therapy in patients with bor-
derline resectable PDAC. The data presented here suggest that the
change in serum CA 19-9 that occurs during the administration of
NT can be used clinically as a surrogate of treatment response and
as a marker of longterm prognosis. Among 141 patients with
borderline resectable PDAC who presented to MDACC with
abnormal levels of CA 19-9 and who were treated with chemo-
therapy and/or chemoradiation prior to planned resection, CA
19-9 declined from baseline in 82% (116 of 141) and normalized
in 33% (47 of 141) of patients. Failure of the CA 19-9 level to
decline was an important clinical signal in that 88% (22 of 25) of
patients with a stable or elevated CA 19-9 following NT did not
complete resection, most commonly as a result of the interval
development of metastatic disease. By contrast, CA 19-9 normali-
zation was a favourable clinical indicator associated with pro-
longed OS in both resected and non-resected patients. These
findings support the measurement of serum CA 19-9 both prior
to and following the administration of NT in patients with bor-
derline resectable PDAC, and emphasize its role as an easily
assayed marker that provides insight into the biology of each
patient’s disease and the patient’s likely longterm outcome follow-
ing the completion of multimodal therapy.
Serum CA 19-9 is the most commonly assayed tumour marker
in the clinical management of PDAC. Measurement of CA 19-9
has been incorporated into the clinical staging and treatment
algorithms of both patients with localized and those with meta-
static disease.3–6,22,26 Among patients with ostensibly localized
cancers, CA 19-9 has been used primarily to predict resectability,26
to restrict preoperative laparoscopy to patients with the highest
risk for radiographically occult metastatic disease,13,14 to predict
the utility of adjuvant therapy after resection,6 and to predict the
timing of postoperative recurrence.5 Several small studies have
also investigated CA 19-9 levels in patients treated with chemo-
therapy or chemoradiation prior to surgery in an attempt to char-
acterize the role of this marker in NT sequencing algorithms.27–29
Many of these studies, however, included heterogeneous popula-
tions of patients with advanced disease who were treated in the
absence of a defined plan for resection. In a previous analysis of
174 patients with potentially resectable PDAC treated in two clini-
cal trials of neoadjuvant chemoradiation, the current authors
Post-NT CA 19-9
Pre-NT CA 19-9
1 - Specificity
0.0
0.0
0.2
0.4
0.6
0.8
1.0
0.2 0.4 0.6 0.8 1.0
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Figure 3 Receiver operating characteristic curves displaying asso-
ciations of serum levels of carbohydrate antigen (CA) 19-9 before
and after neoadjuvant therapy (NT) with resection after NT. The
areas under the curve for pre-NT and post-NT CA 19-9 levels were
0.62 [95% confidence interval (CI) 0.52–0.71] and 0.78 (95% CI
0.70–0.86) with optimum cut-off values of 989 U/ml and 106 U/ml,
respectively
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found that patients with low serum CA 19-9 both prior to and
following the administration of NT had more favourable out-
comes compared with those with high levels of CA 19-9, and that
patients in whom CA 19-9 declined over the course of therapy had
more favourable outcomes than those in whom CA 19-9 rose.2
However, the PPVs with respect to resection of both post-NT CA
19-9 and its change from the pre-NT level were similar to that
derived from a standard radiologic and clinical restaging evalua-
tion. Furthermore, both measures had a low NPV for the comple-
tion of resection: that is, a high post-NT level or rise in CA 19-9
during NT did not reliably exclude resection.
As in this group’s previous study of potentially resectable
patients, baseline serum CA 19-9 in patients with borderline
resectable cancers prior to NT has less clinical relevance than the
Table 3 Post-neoadjuvant therapy (NT) serum carbohydrate antigen (CA) 19-9 cut-offs and association with overall survival (OS) in patients
with borderline resectable pancreatic adenocarcinoma
Reached cut-off Did not reach cut-off
Median OS,
months
95% CI Median OS,
months
95% CI P-value
CA 19-9 level after NT, U/ml
Any CA 19-9 decrease (resected patients) 30.4 25.0–35.8 32.0 11.4–52.6 0.510
Any CA 19-9 decrease (non-resected patients) 14.2 12.6–15.8 8.3 5.54–11.1 0.003
CA 19-9 of <1000 U/ml (resected patients) 30.9 26.8–35.0 15.4 a 0.102
CA 19-9 of <1000 U/ml (non-resected patients) 13.6 10.6–16.6 7.9 5.5–10.3 0.011
CA 19-9 of <200 U/ml (resected patients) 30.9 27.1–34.8 25.7 0–58.5 0.813
CA 19-9 of <200 U/ml (non-resected patients) 15.0 12.9–17.1 8.3 5.9–10.7 0.001
CA 19-9 of <100 U/ml (resected patients) 30.4 24.3–36.5 32.0 25.7–38.3 0.733
CA 19-9 of <100 U/ml (non-resected patients) 15.0 12.7–17.3 10.8 9.4–12.2 0.030
CA 19-9 normalizationb (resected patients) 37.9 30.5–45.3 26.0 19.6–32.4 0.020
CA 19-9 normalizationb (non-resected patients) 15.0 7.6–22.4 11.0 9.4–12.6 0.022
aOnly one patient in this cohort.
bNormal CA 19-9: <40 U/ml.
95% CI, 95% confidence interval.
+ +
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P < 0.001
Resected, post-NT CA 19-9 normal (A)
No resection, post-NT CA 19-9 normal (C)
Resected, post-NT CA 19-9 abnormal (B)
No resection, post-NT CA 19-9 abnormal (D)
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Figure 4 Kaplan–Meier estimates of survival in all patients stratified by resection status and carbohydrate antigen (CA) 19-9 normalization
after neoadjuvant therapy (NT)
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CA 19-9 level obtained following therapy or the change in levels
over time. Indeed, in this study, the percentage of patients with an
elevated CA 19-9 level at any tested cut-off value of <1000 U/ml
who did not undergo resection did not differ from the percentage
of patients who did undergo resection. By contrast, among his-
torical patients with localized disease who undergo surgery first,
an elevated CA 19-9 level is an important indicator of the presence
of radiographically occult disease that precludes curative surgery.
The difference in the clinical value of the pretreatment CA 19-9 in
these two groups is likely to reflect the response of the cancer to
the cytotoxic activity of drugs and radiation treatments adminis-
tered in the preoperative setting, and a consequent alteration in
the relationship between the baseline tumour marker and tumour
burden over the course of therapy. The relative importance of the
post-NT CA 19-9 level or its change in response to chemotherapy
and/or chemoradiation administered in the preoperative setting is
analogous to the use of carcinoembryonic antigen (CEA) in
patients with colorectal cancer, in whom the post-treatment
marker level is an important indicator of prognosis.30–32
In patients with borderline resectable PDAC, the CA 19-9
changes observed over the course of NT appear to provide insight
into tumour biology and treatment response, which, unlike in
other solid tumours, cannot be evaluated radiographically. In a
previous study of 122 patients with borderline resectable PDAC,
only 15 (12%) showed a change in tumour size sufficient to meet
RECIST parameters for a treatment response following the
administration of NT, and only one (1%) patient showed radio-
graphic evidence of a reduction in vascular involvement sufficient
to improve anatomic stage. Furthermore, the median duration of
OS in patients who underwent resection in the absence of a radio-
graphic ‘response’ was similar to that in patients whose tumours
decreased in size.17 However, tumour response to therapy can be
estimated histopathologically. In a study of 223 patients who
received NT prior to resection of PDAC, the resection specimens
of 42 patients contained minimal or no residual cancer. These
patients with minimal or no residual cancer had higher rates of
negative margins, lower rates of positive lymph nodes, and longer
overall and recurrence-free survival than patients with more
residual disease.16 Of course, this information can only be gath-
ered after resection and thus cannot contribute to preoperative
counselling.
One of the most important findings reported here is that the
normalization of CA 19-9 following NT is a marker for improved
OS in both patients who do and those who do not undergo resec-
tion. Indeed, among these patients with borderline resectable
primary tumours, patients in whom serum CA 19-9 normalized
and who subsequently underwent resection following NT had a
median OS of 37.9 months. Even among non-resected patients CA
19-9 normalization was associated with a prolonged median sur-
vival relative to that in patients in whom CA 19-9 did not nor-
malize, reflecting a tumour response to the chemotherapy and
chemoradiation regimens used. Future studies should explore
how CA 19-9 data can be incorporated into individualized treat-
ment algorithms. For example, a persistent elevation in serum CA
19-9 following an initial course of therapy might be considered as
an indication of the need to switch cytotoxic agents prior to
surgery. It could also serve as a trigger for a staging laparoscopy
prior to chemoradiation. The present authors have typically per-
formed laparoscopy prior to surgery and have chosen not to
laparoscope patients with borderline PDAC prior to the initiation
of systemic chemotherapy as the identification of occult meta-
static disease would not change the initial chemotherapy regimen.
However, laparoscopies performed earlier in the treatment algo-
rithm according to CA 19-9 findings might save patients from the
morbidities associated with ineffective local therapies in the pres-
ence of extrapancreatic disease. In addition, the prognosis esti-
mated by CA 19-9 might also be used in the planning of
personalized postoperative surveillance strategies designed to
optimize cost-effectiveness.24
It should be emphasized that although CA 19-9 is routinely
assayed in all patients at the study institution, clinical staging is
accomplished using defined clinical classifications based upon
local tumour anatomy and crude assessments of tumour biology
and patient condition and comorbidities.18 The preoperative regi-
mens formulated by the multidisciplinary group are then deliv-
ered until completion or tumour progression. Finally, surgeons
use objective indications for resection following the administra-
tion of NT, which include: (i) a performance status sufficient for
major abdominal surgery; (ii) the adequate optimizing of comor-
bidities, and (iii) the absence of any radiographic or intraoperative
detection of tumour progression. Although CA 19-9 is not gener-
ally used as a primary factor in decision making on the use of
surgical resection following the completion of non-operative
therapy, the possibility that CA 19-9 levels influenced decision
making in some of the patients reported here cannot be entirely
discounted.
Other strengths and limitations of this study also warrant dis-
cussion. Firstly, this retrospective analysis of patients treated at a
single institution is subject to the biases and limitations inherent
in any retrospective study. However, this study evaluated one of
the largest reported cohorts of patients with borderline resectable
PDAC in whom tumours were staged using objective radiographic
criteria and classified using consensus guidelines. Follow-up in
these patients was generally unbiased. This institution’s prospec-
tive pancreatic cancer patient database has an overall follow-up
rate of 92% attributable to a systematic intensive surveillance
programme.25 Another potential limitation of this analysis is that
40 of 210 (19%) patients were excluded for reasons of hyperbi-
lirubinaemia and the fact that CA 19-9 is not routinely checked
after endobiliary stent placement. This is important because
hyperbilirubinaemia can cause an elevation in CA 19-9 irrespec-
tive of tumour burden and might introduce significant error into
analyses in which pre-NT CA 19-9 levels associated with and
without jaundice are considered. This may account for the wide
spectrum of pretreatment CA 19-9 cut-offs proposed in the sur-
gical literature. The extent to which any change in CA 19-9 levels
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reflects tumour response and not biliary decompression depends
on all CA 19-9 levels being measured in the absence of obstructive
jaundice.
In conclusion, CA 19-9 decreases in four of five patients under-
going NT for borderline resectable PDAC. Although conventional
radiographic ‘response’ criteria are of little value in the manage-
ment of patients with this stage of disease, CA 19-9 appears to
represent a dynamic marker of tumour biology and response to
NT. A normalization of CA 19-9 following NT is associated with a
favourable prognosis in both non-resected and resected patients
with borderline resectable PDAC.
Acknowledgements
The authors thank Joel Cox for his management of the University of Texas MD
Anderson Cancer Center departmental pancreatic surgery database.
Conflicts of interest
None declared.
References
1. Ballehaninna UK, Chamberlain RS. (2012) The clinical utility of serum CA
19-9 in the diagnosis, prognosis and management of pancreatic adeno-
carcinoma: an evidence-based appraisal. J Gastrointest Oncol 3:105–
119.
2. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW
et al. (2010) Serum CA 19-9 as a marker of resectability and survival in
patients with potentially resectable pancreatic cancer treated with neo-
adjuvant chemoradiation. Ann Surg Oncol 17:1794–1801.
3. Maithel SK, Maloney S, Winston C, Gonen M, D'Angelica MI, Dematteo
RP et al. (2008) Preoperative CA 19-9 and the yield of staging laparos-
copy in patients with radiographically resectable pancreatic adenocarci-
noma. Ann Surg Oncol 15:3512–3520.
4. Satoi S, Yanagimoto H, Toyokawa H, Inoue K, Wada K, Yamamoto T et al.
(2011) Selective use of staging laparoscopy based on carbohydrate
antigen 19-9 level and tumour size in patients with radiographically
defined potentially or borderline resectable pancreatic cancer. Pancreas
40:426–432.
5. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H et al.
(2012) Serum CA 19-9 is a significant predictor among preoperative
parameters for early recurrence after resection of pancreatic adenocar-
cinoma. J Gastrointest Surg 16:977–985.
6. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD et al.
(2012) The prognostic and predictive value of serum CA 19.9 in pancre-
atic cancer. Ann Oncol 23:1713–1722.
7. Martin LK, Wei L, Trolli E, Bekaii-Saab T. (2012) Elevated baseline CA
19-9 levels correlate with adverse prognosis in patients with early- or
advanced-stage pancreas cancer. Med Oncol 29:3101–3107.
8. Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L et al.
(2013) Re-resection for isolated local recurrence of pancreatic cancer is
feasible, safe, and associated with encouraging survival. Ann Surg Oncol
20:964–972.
9. Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W
et al. (2010) Estimating prognosis and palliation based on tumour marker
CA 19-9 and quality of life indicators in patients with advanced pancreatic
cancer receiving chemotherapy. Br J Cancer 103:1318–1324.
10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L,
Linehan DC. (2009) Pretreatment assessment of resectable and border-
line resectable pancreatic cancer: expert consensus statement. Ann Surg
Oncol 16:1727–1733.
11. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang
H et al. (2006) Borderline resectable pancreatic cancer: definitions, man-
agement, and role of preoperative therapy.AnnSurgOncol 13:1035–1046.
12. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB et al. (2008)
Borderline resectable pancreatic cancer: the importance of this emerging
stage of disease. J Am Coll Surg 206:833–846; discussion 846–848.
13. National Comprehensive Cancer Network. (2012) Pancreatic adenocar-
cinoma Version 2.2012. NCCN Clinical Practice Guidelines in Oncology.
Fort Washington, PA: NCCN.
14. Katz MH, Pisters PW, Lee JE, Fleming JB. (2011) Borderline resectable
pancreatic cancer: what have we learned and where do we go from here?
Ann Surg Oncol 18:608–610.
15. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB,
Casper ES et al. (2012) Pancreatic adenocarcinoma, Version 2.2012 fea-
tured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10:703–
713.
16. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H
et al. (2012) Histologic grading of the extent of residual carcinoma fol-
lowing neoadjuvant chemoradiation in pancreatic ductal adenocarci-
noma: a predictor for patient outcome. Cancer 118:3182–3190.
17. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R et al.
(2012) Response of borderline resectable pancreatic cancer to neoadju-
vant therapy is not reflected by radiographic indicators. Cancer
118:5749–5756.
18. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN et al.
(2012) Defined clinical classifications are associated with outcome of
patients with anatomically resectable pancreatic adenocarcinoma treated
with neoadjuvant therapy. Ann Surg Oncol 19:2045–2053.
19. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW
et al. (2008) Preoperative gemcitabine-based chemoradiation for patients
with resectable adenocarcinoma of the pancreatic head. J Clin Oncol
26:3496–3502.
20. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW et al.
(2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-
based chemoradiation for resectable adenocarcinoma of the pancreatic
head. J Clin Oncol 26:3487–3495.
21. Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N et al. (2008)
Development of an integrated biospecimen bank and multidisciplinary
clinical database for pancreatic cancer. Ann Surg Oncol 15:1356–1366.
22. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ et al. (2007) The
use of adjusted preoperative CA 19-9 to predict the recurrence of resect-
able pancreatic cancer. J Surg Res 140:31–35.
23. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA et al. (2009)
Longterm survival after multidisciplinary management of resected pan-
creatic adenocarcinoma. Ann Surg Oncol 16:836–847.
24. Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW et al.
(2013) Frequency and intensity of postoperative surveillance after cura-
tive treatment of pancreatic cancer: a cost-effectiveness analysis. Ann
Surg Oncol 20:2197–2203.
25. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN et al.
(2012) Yield of clinical and radiographic surveillance in patients with
resected pancreatic adenocarcinoma following multimodal therapy. HPB
14:365–372.
HPB 437
HPB 2014, 16, 430–438 © 2013 International Hepato-Pancreato-Biliary Association
26. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C et al. (2012) CA
19-9 in potentially resectable pancreatic cancer: perspective to adjust
surgical and perioperative therapy. Ann Surg Oncol 20:2188–2196.
27. Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy
MF et al. (2008) Full-dose gemcitabine with concurrent radiation therapy
in patients with non-metastatic pancreatic cancer: a multicentre phase II
trial. J Clin Oncol 26:942–947.
28. Ohara K, Tatsuzaki H, Molotkova NG, Oda T, Yuzawa K, Saida Y et al.
(2001) Utility of serum CA 19-9 monitoring in preoperative radiotherapy
for pancreatic cancer. Hepatogastroenterology 48:859–863.
29. Willett CG, Daly WJ, Warshaw AL. (1996) CA 19-9 is an index of response
to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J
Surg 172:350–352.
30. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. (2009) Serum carcinoem-
bryonic antigen monitoring after curative resection for colorectal cancer:
clinical significance of the preoperative level. Ann Surg Oncol 16:3087–
3093.
31. Park JW, Lim SB, Kim DY, Jung KH, Hong YS, Chang HJ et al. (2009)
Carcinoembryonic antigen as a predictor of pathologic response and a
prognostic factor in locally advanced rectal cancer patients treated with
preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol
Phys 74:810–817.
32. Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S et al. (2010)
Clinical significance of CEA and CA 19-9 in postoperative follow-up of
colorectal cancer. Ann Surg Oncol 17:2349–2356.
438 HPB
HPB 2014, 16, 430–438 © 2013 International Hepato-Pancreato-Biliary Association
